Inhibition of Fatty Acid Synthase Attenuates CD44-Associated Signaling and Reduces Metastasis in Colorectal Cancer by Zaytseva, Yekaterina Y. et al.
University of Kentucky
UKnowledge
Markey Cancer Center Faculty Publications Cancer
3-15-2012
Inhibition of Fatty Acid Synthase Attenuates
CD44-Associated Signaling and Reduces
Metastasis in Colorectal Cancer
Yekaterina Y. Zaytseva
University of Kentucky, yyzayt2@uky.edu
Piotr G. Rychahou
University of Kentucky, piotr.rychahou@uky.edu
Pat Gulhati
University of Kentucky
Victoria Allison Elliott
University of Kentucky, victoria.elliott@uky.edu
William Conan Mustain
University of Kentucky, wc.mustain@uky.edu
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/markey_facpub
Part of the Cancer Biology Commons, and the Oncology Commons
This Article is brought to you for free and open access by the Cancer at UKnowledge. It has been accepted for inclusion in Markey Cancer Center
Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Repository Citation
Zaytseva, Yekaterina Y.; Rychahou, Piotr G.; Gulhati, Pat; Elliott, Victoria Allison; Mustain, William Conan; O'Connor, Kathleen;
Morris, Andrew J.; Sunkara, Manjula; Weiss, Heidi L.; Lee, Eun Young; and Evers, B. Mark, "Inhibition of Fatty Acid Synthase
Attenuates CD44-Associated Signaling and Reduces Metastasis in Colorectal Cancer" (2012). Markey Cancer Center Faculty
Publications. 122.
https://uknowledge.uky.edu/markey_facpub/122
Authors
Yekaterina Y. Zaytseva, Piotr G. Rychahou, Pat Gulhati, Victoria Allison Elliott, William Conan Mustain,
Kathleen O'Connor, Andrew J. Morris, Manjula Sunkara, Heidi L. Weiss, Eun Young Lee, and B. Mark Evers
Inhibition of Fatty Acid Synthase Attenuates CD44-Associated Signaling and Reduces Metastasis in Colorectal
Cancer
Notes/Citation Information
Published in Cancer Research, v. 72, issue 6, p. 1504-1517.
© 2012 American Association for Cancer Research.
The copyright holder has granted the permission for posting the article here.
The document available for download is the authors' post-peer-review final draft of the article.
Digital Object Identifier (DOI)
https://doi.org/10.1158/0008-5472.CAN-11-4057
This article is available at UKnowledge: https://uknowledge.uky.edu/markey_facpub/122
Inhibition of Fatty Acid Synthase Attenuates CD44-Associated
Signaling and Reduces Metastasis in Colorectal Cancer
Yekaterina Y. Zaytseva1,2, Piotr G. Rychahou1,2, Pat Gulhati1,2, Victoria A. Elliott1, William
C. Mustain1,2, Kathleen O’Connor1, Andrew J. Morris4,5, Manjula Sunkara4,5, Heidi L.
Weiss1,2, Eun Y. Lee1,2,3, and B. Mark Evers1,2
1Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA
2Department of Surgery, University of Kentucky, Lexington, Kentucky, USA
3Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, Kentucky,
USA
4Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky, USA
5Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA
Abstract
Fatty Acid Synthase (FASN) and ATP-citrate lyase (ACLY), key enzymes of de novo lipogenesis,
are significantly upregulated and activated in many cancers and portend poor prognosis. Even
though the role of lipogenesis in providing proliferative and survival advantages to cancer cells
has been described, the impact of aberrant activation of lipogenic enzymes on cancer progression
remains unknown. In this study, we found that elevated expression of FASN is associated with
advanced stages of colorectal cancer (CRC) and liver metastasis, suggesting that it may play a role
in progression of CRC to metastatic disease. Targeted inhibition of lipogenic enzymes abolished
expression of CD44, a transmembrane protein associated with metastases in several cancers
including CRC. In addition, inhibition of lipogenic enzymes and reduced expression of CD44
attenuated the activation of MET, Akt, FAK, and paxillin, which are known to regulate adhesion,
migration and invasion. These changes were consistent with an observed decrease in migration
and adhesion of CRC cells in functional assays and with re-organization of actin cytoskeleton
upon FASN inhibition. Despite the modest effect of FASN inhibition on tumor growth in
xenografts, attenuation of lipogenesis completely abolished establishment of hepatic metastasis
and formation of secondary metastasis. Together, our findings suggest that targeting de novo
lipogenesis may be a potential treatment strategy for advanced CRC.
Keywords
Fatty Acid Synthase (FASN); ATP-citrate lyase (ACLY); colorectal cancer (CRC); lipogenic
enzymes
INTRODUCTION
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the U.S. (1)
The prognosis and life expectancy of patients with CRC are primarily determined by
presence or absence of metastases, not by growth of the primary tumor (2). Treatment
Send correspondence to: B. Mark Evers, MD, Markey Cancer Center, University of Kentucky, 800 Rose Street, CC140, Lexington,
KY 40536-0093, Telephone: (859) 323-6556, Fax: (859) 323-2074, mark.evers@uky.edu.
NIH Public Access
Author Manuscript
Cancer Res. Author manuscript; available in PMC 2013 March 15.
Published in final edited form as:
Cancer Res. 2012 March 15; 72(6): 1504–1517. doi:10.1158/0008-5472.CAN-11-4057.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
options for metastatic CRC are limited and more selective therapeutic targets are needed to
improve survival.
The signaling networks that determine progression of cancer to a metastatic phenotype
include multiple alterations in the oncogenic pathways and significant changes in cellular
metabolism. The fact that, in contrast to normal cells, the majority of fatty acids in
malignant cells are derived from de novo lipogenesis regardless of the availability of
extracellular lipids, suggests the importance of upregulation of endogenous lipid
biosynthesis in malignant transformation (3). ATP-citrate lyase (ACLY) and fatty acid
synthase (FASN), the key enzymes of de novo lipogenesis, are significantly upregulated in
many cancers including CRC (3). Indeed, expression of FASN was increased in 86% of
aberrant crypt foci (ACF) compared with that of adjacent normal colonic mucosa (4).
Furthermore, metabolic profiling of CRC has shown an overall increase in the lipid content
of polyps and tumors (5).
Neoplastic lipogenesis provides a selective proliferative and survival advantage and
contributes to drug resistance in cancer cells (6–8). However, the impact of aberrant
activation of lipogenic enzymes on metastases remains unknown. Expression of FASN is
highest in metastatic tumors and correlates with decreased survival and disease recurrence in
several tumor types (9, 10). Interestingly, proteomic characterization of CRC cell lines
indicates that an increased expression of lipogenic enzymes is associated with a more
aggressive metastatic phenotype (11). Furthermore, pharmacological inhibition of FASN
provides indirect evidence of a possible connection between activation of lipogenesis and
metastatic behavior of cancer cells (12–14).
Progression to a metastatic phenotype is associated with differential expression of proteins
on the cell surface (11, 15). CD44, a transmembrane glycoprotein with multiple isoforms, is
implicated in tumor progression and metastasis (16). Expression of CD44 is increased in
CRC and correlates with poor clinical outcome (17, 18). The role of CD44 in metastases
might be linked to its interaction with receptor tyrosine kinases such as c-MET, a proto-
oncogene involved in tumor growth, invasion, and metastasis (19). Association of c-MET
with CD44 isoforms at the plasma membrane appears to be essential for activation of c-
MET and downstream signaling in CRC (20).
In the present study, we determined the role of lipogenic enzymes in metastatic CRC. We
demonstrate that in human tissue arrays, FASN is progressively increased with advancing
stages of CRC. For the first time, this study establishes the link between expression of
lipogenic enzymes and CD44. We show that inhibition of ACLY and FASN dramatically
reduces expression of CD44 and attenuates CD44-associated signaling. We further
demonstrate that suppressed expression of FASN decreases the tumorigenic and metastatic
potential of CRC cells in vitro and in vivo. Collectively, our data suggest that upregulation
of de novo lipogenesis is a critical step in CRC progression to metastases and that a better
understanding of the link between metabolic changes in cancer cells and development of
metastasis may lead to novel strategies to prevent and/or control advanced CRC.
MATERIALS AND METHODS
Cell lines, lentiviral transduction, siRNA
Human CRC lines KM20 and HCT116 were used as described previously and their identity
was authenticated at the Johns Hopkins Genetic Resources Core Facility (Baltimore, MD) in
October 2010, as previously reported (21). HT29 cells were purchased from ATCC
(Rockville, MD). For generation of stable knockdown KM20, HT29, and HCT116 cell lines,
the lentiviral transduction particles containing shRNA for ACLY (SHCLNV-NM_001096),
Zaytseva et al. Page 2
Cancer Res. Author manuscript; available in PMC 2013 March 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FASN (SHCLNV-NM_004104), or non-target shRNA (CHC002V) in pLKO.1-puro
plasmid were purchased from Sigma (St. Louis, MO). Cells were transduced with virus in
the presence of polybrene (10µg/mL) for 24h and then selected on puromycin (10µg/mL).
ON-TARGET plus CD44 siRNAs (LU-00999907, LU-00999908) and control siRNA
(D-001810-10) were purchased from Dharmacon (Lafayette, CO) and used in a
concentration of 100µM.
Antibodies
Antibodies for Western blot and immunofluorescent staining were purchased from Cell
Signaling (Danvers, MA): FASN (#3180), ACLY (#4332), pACLY (#4331), CD44 (#3570),
pMET (#3129), MET (#3148), pSrc (#2101), Src (#2109), pAkt (#4058L), Akt (#4691L), p-
paxillin (#2541), paxillin (#2542), pFAK (#3283), FAK (#3285), and RhoA (#2117).
Human tissue arrays
The CO702 tissue array (US Biomax, USA), A203 (IV) tissue array (AccuMax, Japan), and
FASN antibody (Cell Signaling, Danvers, MA) were purchased. Scoring was performed
blindly by a pathologist according to a semiquantitative method (21). The extent score was
assessed on a scale of 0–3 (no positive cells = 0, <10% = 1, 10–50% = 2, positive staining of
>50% = 3); the intensity score was also measured on a scale of 0–3 (negative = 0, weak = 1,
moderate = 2, strong = 3). The immunoreactive score was obtained by summing these two
scores.
Analysis of de novo lipogenesis
De novo palmitate synthesis was analyzed by stable isotope labeling. Cells were plated in
normal growth medium. On Day 2, medium was replaced with medium containing sodium
acetate (2–13C, 99%, Cambridge Isotope Laboratories, Andover, MA) for 20h at a
concentration of 10mM. Extraction of the lipids was performed as described previously (22)
in the presence of an internal standard. Fatty acids were converted to 3-acyloxymethyl-1-
methylpyridinium iodide (AMPP) derivatives and the AMPP derivative of palmitic acid was
quantified using a Shimadzu HPLC coupled to ABI 4000 Q-Trap hybrid linear ion trap triple
quadrupole mass spectrometer operated in positive ESI mode as previously described (23).
The instrument was operated in multiple reaction monitoring mode and the precursor
product ion pairs monitored were 362.2/124.5 which represent the [M+H]+ mass of the
AMPP derivative of palmitic acid and a fragment ion containing the N-pyridyl moiety.
Enrichment of 13C was determined from the ratio of integrated peak areas corresponding to
the mz/363.2/124.5 and the M+1 isotopomer 362.2/124.5 precursor/product ion pairs.
qRT- PCR
Total RNA was isolated using an RNeasy mini kit (Qiagen, Valencia, CA). cDNA was
synthesized using a high capacity cDNA reverse transcription kit (Applied Biosystems,
Austin, TX). qRT-PCR was performed using a TaqMan Gene Expression Master Mix
(#4369016) according manufacture protocol and TaqMan probes for human CD44 (ID
Hs1075862_m1) and human GAPDH (# 4333764F) (Applied Biosystems, Austin, TX).
Flow cytometry analysis and cell sorting
Cells were labeled with 2µg/ml CD44–FITC antibody (Abcam, Cambridge, MA) per 5×106
cells. For cell sorting, cells were washed and resuspended in Basic Sorting Buffer. For
analysis of CD44 expression on cell surface, cells were resuspended in PBS, 10% FCS, 1%
sodium azide. Cell analysis and cell sorting were performed by the UK Flow Cytometry
Service Facility.
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Transwell migration assay
A Boyden chamber migration assay with collagen-coated Transwells was performed with
KM20 and HT29 cells for 20h as described previously (21). FBS 10% was used as a
chemoattractant. Cells were counted in four different fields with an inverted microscope.
Endothelial cell adhesion assay
CRC cells were labeled with Calcein AM (2.5µg/mL final concentration) at 37°C, added
atop a monolayer of human microvascular endothelial cells from lungs (HMVEC-L) for 30
min. Prior to the experiment, HMVEC-L cells were activated with 10ng/mL of TGFα for
4h. Unattached cells were removed by washing with PBS (5×). Three images per well were
taken to count attached cells.
In vivo studies
Male athymic nudenu/nu mice (5–6 weeks old) (Charles River Laboratories, Wilmington,
MA) were housed in the Markey Cancer Center Small Animal Facility. All procedures were
performed using protocols approved by the UK Animal Care and Use Committee. To
establish CRC xenografts, mice were injected with 1×106 cells/100µl of KM20 or HT29
with non-targeting control (NTC) shRNA and FASN shRNA (5 mice/group). To assess
establishment of hepatic metastasis, HT29-GFP-Luc cells (2×106 cells/100µl) were injected
intrasplenically as previously described (24). For experimental metastasis models, control
and stable knockdown HT29-GFP-Luc cells or KM20-GFP-Luc (2×106 cells/300µl) were
injected into the tail vein of athymic nude mice (n=4 and n=5 per group, respectively). To
monitor metastasis, mice were anesthetized with isoflurane, given a single i.p. dose of
150mg/kg D-luciferin in PBS and imaged 8 min after injection (IVIS Spectrum, Caliper
Sciences). Results were analyzed using Living Image 3.0 software.
Statistical methods
ANOVA with test for linear trend and pairwise comparisons was performed to compare
immunoreactivity scores in normal mucosa and CRC of various stages. ANOVA was also
employed for multiple group comparison of shRNA (ACLY and FASN) with NTC for
CD44 levels while two-sample t-test or Wilcoxon rank sum test was used for two group
comparisons of migration, number of colonies and tumor weight between FASN vs. NTC.
Comparison of log values of tumor volume measured over time was performed using a
linear mixed model. Analyses were performed separately for each cell line.
RESULTS
FASN is highly expressed in primary CRCs and liver metastases
Evaluations of FASN in human ACF and primary CRCs have revealed elevated expression
of this enzyme in early stages of colorectal tumorigenesis as compared to normal mucosa (4,
25–27). To extend these studies, we analyzed expression of FASN in CRC clinical samples
by immunohistochemistry (Fig. 1A). Expression of FASN was detected in the cytoplasm in
all stages of primary CRC, though some variability was observed within different regions of
individual tumor cores. Statistical evaluation of immunoreactivity scores demonstrated
increased expression of FASN in Stages II–IV CRC as compared to normal mucosa.
Analysis of primary tumors, matched liver metastases and normal colonic mucosa from
Stage IV patients demonstrated significantly higher expression of FASN in both the primary
CRC and liver metastasis as compared to normal colon mucosa (Supplementary Fig. 1).
We also tested expression of ACLY and FASN in a panel of CRC cell lines. Consistent with
results obtained from human tissue arrays, Western blot analysis demonstrated high
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expression/activation of lipogenic enzymes (Fig. 1B). These data suggest that enhanced de
novo lipid biosynthesis may play a role in progression of primary CRC to metastatic disease.
Inhibition of lipogenic enzymes decreases expression of CD44
CD44 and c-Met have been implicated in CRC metastasis via regulation of tumor cell
growth, adhesion, migration and invasion (16, 28, 29). Considering that tumor-produced
fatty acids preferentially partition into lipid rafts (30), we hypothesized that altered
expression of lipogenic enzymes may affect CD44 and c-Met since their functions have been
attributed to these rafts (31, 32). First, we analyzed expression of CD44 and c-Met in a panel
of CRC cell lines. CD44 variant isoforms (CD44v), which are primarily implicated in
regulation of metastasis, are highly expressed in most cell lines (Fig. 2A). In contrast with
other cell lines, the non-metastatic SW480 cell line expresses a low level of CD44v and a
high level of CD44 standard isoform (CD44s). Activation of c-Met was observed in KM20,
HT29, and HCT116 cell lines, and we used these three cell lines to establish a stable
shRNA-mediated knockdown of either ACLY or FASN to investigate the role of de novo
lipogenesis in metastatic CRC.
To confirm inhibition of lipid biosynthesis when ACLY and FASN are inhibited, cells were
exposed to stable isotope-labeled acetate and its incorporation into palmitate was measured
by mass spectrometry. Targeted inhibition of ACLY and FASN led to a 60–100% decrease
in de novo palmitate synthesis (Fig. 2B). Interestingly, reduced expression of ACLY and
FASN was also associated with changes in cellular morphology (Supplementary Fig. 2). We
demonstrate that inhibition of ACLY and FASN significantly decreases expression of the
CD44 protein. A more pronounced inhibition of CD44 was observed in cells with
knockdown of FASN compared with that of ACLY (Fig. 2C). Treatment of HT29 cells with
C-75, a synthetic inhibitor of enzymatic activity of FASN, also led to a dose-dependent
decrease in expression of CD44 (Fig. 2D). Interestingly, upregulation of FASN expression
by transient transfection of myristoylated, constitutively active form of Akt1 (myr-Akt1) or
Akt2 (myr-Akt2) had an opposite effect and increased expression of CD44 in HT29 cells
(Fig. 2E).
To further evaluate the correlation of CD44 expression and FASN, we performed direct
labeling of FASN knockdown HT29 cells with the CD44-FITC antibody. These cells were
cultured for 3 weeks prior to the experiment and demonstrated a mixed population of cells
with differential expression of FASN as confirmed by immunofluorescent staining (data not
shown). CD44-FITC labeled cells were sorted based on the level of CD44 expression. Cells
with low expression of CD44 demonstrated concomitant reduction of FASN expression
(Fig. 2F).
To elucidate the mechanism for the downregulation of CD44 in ACLY and FASN
knockdown cells, we assessed the level of CD44 mRNA in KM20, HT29, and HCT116 cell
lines each with stable knockdown of either ACLY or FASN. We observed a slight decrease
in CD44 mRNA in HCT116 and KM20, but not in the HT29 cell line (Fig. 2G). It has been
previously shown that expression of CD44 can be regulated by posttranscriptional
modifications such as palmitoylation (32). To test the possible involvement of this
mechanism in the regulation of CD44 expression in CRC cells, we used 2-Bromopalmitate
(2-BP), a non-metabolizable palmitate analog, to block the incorporation of palmitate into
proteins. HT29 NTC and FASN knockdown cells were treated with either DMSO or 200µM
of 2-BP, labeled with CD44-FITC antibody, and analyzed by flow cytometry. The analysis
demonstrated a 2-fold decrease in signal intensity on the cell surface in FASN knockdown
and 2-BP treated cells versus control HT29 cells (Supplementary Fig. 3A). Consistent with
these data, subcellular fractionation revealed that expression of CD44 in the membrane
fraction is significantly lower in FASN knockdown and 2-BP treated cells compared with
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control HT29 cells (Supplementary Fig. 3B). Together, these data suggest that de novo
lipogenesis regulates expression of CD44 at a post-transcriptional level, possibly by altering
its palmitoylation.
Inhibition of lipogenic enzymes attenuates c-Met signaling in CRC cells
Recent studies have shown a functional link between expression of FASN and activation of
c-Met (33). To test whether a decrease in expression of lipogenic enzymes affects activity of
c-Met in CRC, we first analyzed the expression and activation of c-Met in KM20 and HT29
with stable knockdown of ACLY and FASN. As shown in Fig. 3A, phosphorylation of Tyr
1234/1235 in the c-Met kinase domain is inhibited by knockdown of FASN in KM20 cells
and by knockdown of both ACLY and FASN in HT29 cells.
To further confirm that attenuation of c-Met signaling is due to inhibition of lipogenic
enzymes, we serum-starved HT29 and KM20 cells (control, ACLY and FASN knockdown)
for 24h and then treated them with 10 ng/ml of hepatocyte growth factor (HGF), a c-Met
receptor ligand, for 20 min. Consistent with data from the previous experiment, activation of
c-Met by HGF was prevented by knockdown of FASN in both KM20 and HT29 cell lines
(Fig. 3B).
To test whether changes in activity of c-MET are CD44-dependent, KM20 and HT29 cells
were transiently transfected with two different CD44 siRNAs or control siRNA. As shown
in Fig. 3C, inhibition of CD44 decreases c-MET activity in HT29, but not in KM20 cells.
Together, these findings suggest that upregulation of lipogenesis during cancer progression
regulates c-Met signaling.
Expression of FASN regulates CRC cell growth, adhesion, and migration
An important pro-metastatic characteristic of cancer cells is their ability to grow in an
anchorage-independent manner. KM20 and HT29 cells (control and FASN knockdown)
were tested for their ability to grow without attaching to a substrate using soft agar assay. In
both cell lines we observed a significant decrease in the number of colonies formed when
expression of FASN was inhibited (Fig. 4A).
Tumor cell intravasation and extravasation are important steps in metastasis and require
cancer cells to interact and adhere to endothelial cells. In CRC, CD44 is implicated in
regulation of adherence of cancer cells to endothelial cells and their subsequent
transendothelial migration (34). To test whether inhibition of FASN can affect the ability of
CRC cells to attach to endothelial cells, we used control and FASN knockdown KM20 and
HT29 cells labeled with Calcein AM. Cells were added atop a monolayer of HMVEC-L pre-
activated with TGFα, and incubated for 30 min. Unattached cells were removed by multiple
washes. Data demonstrated that downregulation of FASN in KM20 and HT29 cells impairs
their ability to attach to endothelial cells (Fig. 4B).
Enhanced cell migration is associated with a metastatic phenotype. The results from the
Transwell migration assay demonstrated that inhibition of FASN impairs migration in both
KM20 and HT29 cell lines (Fig. 4C). Collectively, these findings suggest that de novo
lipogenesis plays a significant functional role in progression of CRC.
Inhibition of lipogenic enzymes alters the signaling network that regulates adhesion and
motility in CRC
The cooperation between CD44 and c-Met at the plasma membrane and their dynamic
interactions with multiple downstream molecules leads to activation of the signaling
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network that regulates cell growth, adhesion, and migration (16). Activation of tyrosine
kinase Src by c-Met contributes to the metastatic potential of CRC cells via regulation of the
actin cytoskeleton and modulation of the formation of adhesive structures (35). Furthermore,
expression of CD44 and activation of c-MET promote phosphorylation of focal adhesion
kinase (FAK) and promote cell motility (36). Interestingly, cooperation of Src and FAK
kinases leads to phosphorylation of paxillin and also contributes to stimulation of cell
motility (37) (Fig. 5A). Our data demonstrates that inhibition of expression of ACLY and
FASN in KM20 and HT29 decreases phosphorylation of Src (Fig. 5B). Since
phosphorylation of Src is associated with downstream activation of FAK and paxillin, we
examined expression of these proteins in HT29 and KM20 with stable knockdown of either
ACLY or FASN. Phosphorylation of paxillin on Tyr 118 was inhibited only by knockdown
of FASN in both KM20 and HT29 cell lines (Fig. 5C). Interestingly, the effect of FASN
knockdown on phosphorylation of FAK was more prominent than the effect of ACLY
knockdown (Fig. 5C). Consistent with several studies showing the connection between
upregulation of lipogenesis and activation of Akt (7, 8), we observed a decrease in
phosphorylation of Akt in both KM20 and HT29 cell lines with stable knockdown of either
ACLY or FASN (Fig. 5D). Furthermore, CD44-dependent expression of RhoA induces
formation of stress fibers and is required for focal adhesion formation (38). Our data
demonstrate a significant decrease in expression of RhoA in ACLY and FASN knockdown
KM20 and HT29 cell lines (Fig. 5D).
To test whether these changes are CD44-dependent, KM20 and HT29 cells were transiently
transfected with CD44 siRNAs or control siRNA and expression/activity of aforementioned
proteins were assessed. As shown in Fig. 5E, inhibition of CD44 significantly decreases
expression of RhoA and activity of Akt in both cell lines. Interestingly, knockdown of CD44
decreased activity of Src and FAK only in HT29 cells and did not affect activity of paxillin
in either cell line (Fig. 5E).
Actin cytoskeleton plays an important role in regulation of cell growth, adhesion, motility
and invasion. Considering that activation of CD44/c-Met and Src affects cell motility by
regulating actin polymerization, depolymerization, and stress fiber formation, we performed
immunofluorescence staining for F-actin. Phalloidin staining demonstrated significant
changes in organization of actin cytoskeleton in cells with FASN knockdown compared to
control cells (Fig. 5E). Furthermore, in agreement with Western blot analysis,
immunofluorescent staining of control and FASN knockdown cells for phospho-FAK and
phospho-paxillin demonstrated a significant decrease in number of focal adhesions in FASN
knockdown KM20 and HT29 cells. Our findings suggest that inhibition of lipogenesis in
CRC cells induces molecular changes and re-organization of actin cytoskeleton, which are
consistent with a less motile and invasive phenotype of cancer cells.
Inhibition of FASN decreases tumor growth and attenuates CRC liver metastasis
It has been previously demonstrated that CRC xenografts treated with C-75 exhibit
inhibition of tumor growth (7). To test whether molecular inhibition of FASN expression
affects tumor growth in vivo, we injected control or FASN knockdown cells subcutaneously
into athymic nude mice. Tumor growth was monitored by measurement of tumor volume
(Fig. 6A). Mice were sacrificed at day 27 after the inoculation and tumor weight was
recorded (Fig. 6B). We observed a slower rate of tumor growth and smaller tumor size in the
FASN-treated mice versus control (p=0.002 for KM20; p=NS for HT29). Expression of
FASN and CD44 in tumors from control and FASN knockdown groups was assessed by
Western blot and showed partial recovery of expression of both proteins at the end of the
experiment (Fig. 6C).
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The liver is the most common site for CRC metastasis and intrasplenic injections
recapitulate the process of liver metastasis. We injected green fluorescent protein (GFP)-
labeled control or FASN knockdown HT29 cells into the spleens of athymic nude mice and
assessed the presence of liver metastasis by GFP imaging and immunohistochemical
analysis at 6 weeks after injection. Primary tumors were observed in 100% of mice in the
control group versus 40% of mice in the FASN knockdown group (Fig. 6D). Liver
metastases were observed in 80% of the mice injected with control HT29 cells, while
complete absence of liver metastasis was observed in mice injected with FASN knockdown
cells (Fig. 6D–E). Presence or absence of liver metastasis was confirmed by H&E staining
(Fig. 6F). Data from these experiments provide support for the role of lipogenesis in tumor
growth and potentially in the metastasis of CRC.
Inhibition of FASN attenuates establishment of CRC metastasis
To further investigate the role de novo lipogenesis plays in metastasis, we examined the
effect of FASN inhibition in an experimental metastasis model in vivo. Luciferase and GFP-
labeled HT29 and KM20 cells with stable knockdown of FASN were injected intravenously
(i.v.) into athymic nude mice and formation of systemic metastasis was assessed by
bioluminescent and fluorescent imaging. All mice in the HT29 control group demonstrated
metastatic nodules (Fig. 7A). The distribution of values for total luciferase signal per animal
is shown in Fig. 7B. Luciferase signal was associated with metastatic nodules on the backs
of the animals and metastasis to the mesenteric lymph nodes. In contrast, none of the
metastatic nodules were formed in the HT29 FASN knockdown group. However,
histological examination of lungs showed the presence of pulmonary micrometastasis in
both the control and FASN knockdown groups (Fig. 7C).
Similar results were obtained when we used another metastatic CRC cell line, KM20.
Systemic metastases were noted in 80% of mice from the control group; however,
knockdown of FASN completely abolished establishment of metastasis as depicted by
luciferase imaging and quantification of total luciferase signal per mouse (Fig. 7D and E).
Surprisingly, in contrast to HT29 inoculated mice, histological examination showed the
presence of pulmonary micrometastasis in 60% of mice in the KM20 control group and
complete absence of micrometastasis in the group injected with FASN knockdown KM20
cells (Fig. 7 F). The presence of pulmonary metastasis in the control group was also
visualized using GFP imaging (Supplementary Fig.4). Taken together, these findings
suggest that overexpression of FASN may play an important role in establishment of CRC
metastasis in vivo.
DISCUSSION
In present study, we investigated the role of de novo lipogenesis in CRC metastases.
Although, multiple studies have focused on the contribution of aberrant expression of
lipogenic enzymes to growth and survival of cancer cells, their role in metastasis remains
unknown (39, 40). Here, we demonstrate an increase in expression of FASN with advancing
stages of CRC, suggesting that FASN may play an important role in the progression of CRC
to metastatic disease. Furthermore, this study demonstrates that inhibition of lipogenic
enzymes decreases expression of CD44 and attenuates the CD44-associated signaling, thus
establishing the novel link between lipid biosynthesis and metastasis. Finally, we show that
targeted inhibition of FASN decreases the tumorigenic potential of CRC cells in vitro and
attenuates establishment of metastasis in two experimental metastasis models in vivo.
Increased expression of CD44 correlates with metastasis in many cancers (16). We showed
that changes in CD44 in CRC cells with inhibited expression of lipogenic enzymes are not
due to transcriptional regulation, but possibly to post-transcriptional modifications of
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protein. CD44 undergoes a sequential proteolytic cleavage and releases CD44 intracellular
domain, which acts as a transcriptional factor and regulates expression of its own gene (36).
This mechanism can explain a slight decrease in CD44 mRNA noted in KM20 and HCT116
cells when lipogenic enzymes are inhibited. Expression of CD44 is dramatically higher in
HT29 cells, so it is possible that CD44 is not dependent on self-regulation.
c-Met is implicated in promotion of metastasis (19). Consistent with studies of diffuse large
B-cell lymphoma and prostate cancer, demonstrating the link between inhibition of FASN
and decreased phosphorylation of c-Met (33, 41), our data show that inhibition of lipogenic
enzymes decreases endogenous activation of c-Met and prevents its activation by HGF in
CRC cells. Interestingly, CD44 is required for c-Met activation and signaling in several
cancers (20, 42). Consistently, we demonstrated that decreased phosphorylation of c-Met in
FASN-depleted cells is CD44-dependent in HT29 cells. The differential effect of CD44
inhibition on c-Met activity in KM20 and HT29 cells can be explained by a significantly
higher level of CD44 expression and c-MET activation in HT29 cells.
Overexpression of FASN in breast cancer cells increased the size and number of colonies in
soft agar (43). In agreement with this study, we demonstrate that inhibition of FASN leads to
a significant decrease in the ability of CRC cells to grow in an anchorage-independent
manner. Additionally, we show that altered lipogenesis regulates attachment of CRC cells to
endothelial cells. Suppressed migration is associated with reduced activity of FASN in
ovarian carcinoma cells (14). Consistently, we also observed a significant decrease in
migration of both KM20 and HT29 cell lines when expression of FASN is inhibited.
Considering that suppression of lipogenic enzymes inhibits expression of CD44 and
decreases activation of c-Met, these functional changes can be explained by alterations in
the signaling network downstream of these two proteins. Our data show that KM20 and
HT29 cells, with inhibited expression of FASN, exhibit significant suppression of Src, FAK,
and paxillin activation, the proteins which are downstream of the CD44/c-Met complex and
implicated in regulation of adhesion dynamics, migration, and invasion of cancer cells (44).
Indeed, the level of FAK receptors and their phosphorylation has been shown to increase
during the adenoma to carcinoma transition of colonic epithelia (45). Furthermore,
activation of Src contributes to anoikis resistance in CRC cells through activation of
phosphatidylinositol 3-kinase (PI3K)/Akt pathway and phosphorylation of Akt (46).
Additionally, overexpression of FASN has been associated with activation of Akt in human
CRC tissue samples (7). Consistent with these findings, we also observed a CD44-dependent
decrease in activation of Akt in HT29 and KM20 cells with inhibited expression of lipogenic
enzymes. Interestingly, inhibition of CD44 attenuates activation of Src and FAK in HT29,
but not in the KM20 cell line, suggesting that the effect of inhibition of lipogenic enzymes
on downstream signaling may be mediated by altered composition of lipid rafts within the
plasma membrane and impairment of activation/function of membrane-associated receptors
or oncoproteins other than CD44 and c-MET (47).
Inhibition of lipogenic enzymes decreases cell growth in several types of cancers (40).
Furthermore, FASN inhibition with C-75 slows growth of CRC xenografts (7). Our findings
are consistent with these studies and demonstrate that inhibition of lipogenesis attenuates the
rate of tumor growth and decreases tumor size in both KM20 and HT29 xenografts.
Interestingly, we observed the partial recovery of FASN expression and a subsequent
increase in expression of CD44 in xenografts, supporting the importance of lipogenesis for
cancer cell survival and growth.
Implantation of cancer cells into the spleens of nude mice results in primary tumor growth
and establishment of hepatic metastases (24). The liver metastasis model primarily evaluates
late stages of metastasis and recapitulates the pattern of colorectal metastasis in humans
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(24). Using this model, we demonstrated that despite detection of primary tumors in both
control and FASN knockdown groups, inhibition of FASN prevented formation of liver
metastasis. Furthermore, results from the experimental metastasis model, carried out with
both KM20 and HT29 cell lines, demonstrated that inhibition of FASN expression blocked
establishment of metastatic nodules in nude mice. The control mice developed multiple
metastatic nodules, predominantly located on the upper back and mesenteric lymph nodes.
This pattern of tumor formation is similar to what was reported in a previous publication by
our laboratory (21). Surprisingly, gross examination of the lungs showed a different effect of
the downregulation of FASN on establishment of microscopic nodules. Knockdown of
FASN in KM20 cells prevented formation of micrometastasis in the lungs; however, its
inhibition in the HT29 cells did not affect formation of tumor nodules. This discrepancy can
likely be explained by the different genetic backgrounds of HT29 and KM20 cell lines. It is
possible that downregulation of FASN has different consequences on modulation of
signaling pathways and metastatic potential in these cell lines. Furthermore, in the
experimental metastasis model, colonization of cells in the lungs does not recapitulate all
steps of the metastatic cascade, and formation of secondary metastatic lesions, which were
depicted by the bioluminescent imaging in our experiment, provides a better model for
evaluation of the metastatic potential of cancer cells. Taken together, data from our in vivo
experiments suggest that downregulation of lipogenesis in cancer cells has a more prominent
effect on metastasis than on the growth of primary tumors.
Due to the strong correlation between de novo lipid biosynthesis and the malignant
phenotype, lipogenic enzymes have become an attractive target for therapeutic intervention.
In particular, FASN, due to its structure and tumor-specific expression, represents a unique
target for cancer drug discovery (48). Despite, multiple publications clearly demonstrating
the role of FASN in cancer cell growth and survival, our study is the first to provide insight
into the contribution of aberrant de novo lipogenesis progression and metastasis of CRC
suggesting that inhibition of FASN may be a potential therapeutic strategy for advanced
stages of CRC. We also demonstrate the link between expression of lipogenic enzymes and
expression of CD44, the protein implicated in establishing of metastasis in many cancers
including CRC. Humanized CD44 antibodies have shown promising results in clinical trials,
but those trials were terminated due to skin-related toxicities (49, 50). The findings
presented in this study open the possibility of targeting CD44 through inhibition of
lipogenesis, thus avoiding antibody-associated toxicities.
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Figure 1.
Expression of FASN in CRC tissues and cell lines. A, expression of FASN in normal colon
mucosa and Stage I–IV primary CRC (US Biomax tissue array CO702 (USA), total 69
cores, ×200 magnification). Immunoreactivity score was determined according to a
semiquantitive method as described in Materials and Methods. B, Cell lysises were prepared
from a panel of human CRC cell lines and immunoblot analysis was performed for FASN,
ACLY, and pACLY expression. β-actin was used as a loading control.
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Figure 2.
Inhibition of ACLY and FASN attenuates expression of CD44. A, immunoblot analysis for
CD44, p-MET, and total MET in a panel of CRC cell lines. β-actin was used as a loading
control. B, de novo lipogenesis was analyzed by stable isotope labeling. Abundance of 13C
acetate in palmitic acid was determined in CRC cell lines with NTC shRNA, ACLY shRNA,
and FASN shRNA by mass spectrometry. Data shown as the ratio of integrated peak areas
(means +/− SD of triplicate determinations). No 13C is an abundance of 13C in unlabeled
cells (a baseline isotope ratio). *, p<0.05 versus control. C, expression of CD44 in KM20,
HT29, and HCT116 CRC cell lines with NTC shRNA, ACLY shRNA, and FASN shRNA.
D, expression of CD44 in HT29 cell line treated with various concentrations of C-75 (µM),
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an inhibitor of FASN, for 24 h. E, expression of FASN and CD44 in HT29 cell line
transiently transfected with myr-Akt1, myr-Akt2, or a control plasmid. F, immunoblot
analysis for FASN and CD44 in HT29 FASN shRNA cells labeled with CD44-FITC
antibody and sorted for expression of CD44. Cells with the lowest (10%) and the highest
(10%) expression of CD44 were used for analysis. G, relative CD44 mRNA levels in KM20,
HT29, and HCT116 cell lines with stable knockdown of ACLY or FASN assessed by real-
time PCR. CD44 mRNA expression was calculated using the ΔΔCt method areas (means +/
− SD of triplicate determinations, * p<0.05 versus control).
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Figure 3.
Inhibition of ACLY and FASN attenuates c-MET signaling. A, Immunoblot analysis for p-
MET and MET in KM20 and HT29 cells lines with NTC shRNA, ACLY shRNA, and
FASN shRNA. B, NTC shRNA, ACLY shRNA, and FASN shRNA KM20 or HT29 cells
were starved for 24 h, then stimulated with HGF (10 ng/ml) for 20 min, lysed, and
immunoblotted for FASN, ACLY, p-MET and MET. C, Immunoblot analysis for p-MET
and MET expression in KM20 and HT29 cells lines transfected with two different CD44
siRNAs or scrambled siRNA as a control.
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Figure 4.
De novo lipid biosynthesis promotes tumorigenic potential of CRC cells. A, KM20 and
HT29 cells with NTC shRNA and FASN shRNA were plated in soft agar and the number of
colonies formed in each well was counted (day 20) using Alpha Innotech Imaging system
and AlphaEase software. Data shown as difference in number of colonies formed in agar by
control and FASN knockdown cells. Data are representative of three independent
experiments. *, p<0.05 versus control. Images of representative wells are shown. B, KM20
and HT29 cells with NTC shRNA and FASN shRNA were added on top of an HMVEC-L
monolayer and cell adhesion was assessed as described in Material and Methods. Data
shown as mean fold changes in number of CRC cells with knockdown of FASN attached to
HMVEC-L cells versus control cells (*, p<0.05). Data are representative of three
independent experiments. Representative images demonstrate adhesion of control and FASN
knockdown cells to HMVEC-L cells. C, Transwell migration assay was carried out with
KM20 and HT29 cells with NTC shRNA and FASN shRNA. Data shown as mean of cell
number migrated per high-power field; *, p<0.05 versus control. Data are representative of
three independent experiments.
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Figure 5.
Inhibition of de novo lipogenesis affects expression of proteins involved in regulation of cell
adhesion, motility, and invasion and induces rearrangement of the actin cytoskeleton. A,
schematic illustration of regulation of cell adhesion, migration and invasion by the CD44/c-
MET complex. B, immunoblot analysis for FASN, ACLY, pSrc, and total Src in KM20,
HT29 cells, and HCT116 cell lines with NTC shRNA, ACLY shRNA, and FASN shRNA.
C, immunoblot analysis for FASN, ACLY, pAkt, total Akt, p-paxillin, and total paxillin in
KM20 and HT29 cells with NTC shRNA, ACLY shRNA, and FASN shRNA. D,
immunoblot for pFAK, total FAK, and RhoA in KM20 and HT29 cells with NTC shRNA,
ACLY shRNA, and FASN shRNA. E, Immunoblot analysis forp Akt, RhoA, pSrc, p-
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paxillin, and p-FAK in KM20 and HT29 cells lines transfected with two different CD44
siRNAs or scrambled siRNA as a control for 48 h or 72 hours. F, total internal reflection
fluorescence imaging of control and FASN knockdown KM20 and HT29 cells stained for F-
actin (green) and either p-paxillin (red) or pFAK (red).
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Figure 6.
Inhibition of FASN suppresses primary CRC tumor growth and establishment of liver
metastasis. A, KM20 and HT29 cells (1 × 106; NTC or FASN shRNA) were injected
subcutaneously into athymic nude mice. Immunoblot analysis for FASN and CD44 in tumor
cells prior to injections shown with tumor volume for days 1–27 (5 mice per group). B,
tumor weights in control and FASN shRNA groups of KM20 and HT29 xenografts. C,
immunoblot analysis for FASN and CD44 in tumor tissues from KM20 and HT29 xenograft
(day 27). D, images of GFP-positive cancer cells in athymic nude mice injected
intrasplenically with HT29-NTC-Luc/GFP or HT29-FASNshRNA-Luc/GFP cells
(abdominal view). Arrows heads indicate primary tumors. E, images of GFP-positive cells in
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liver. F, representative images of histological analysis (H&E staining) of liver metastasis (L,
normal liver; M, metastasis).
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Figure 7.
Inhibition of FASN prevents establishment of CRC metastasis. A, in vivo total-body
bioluminescence images of athymic nude mice in dorsal and ventral positions (IVIS@
Imaging System) injected i.v. with HT29-NTC-Luc or HT29-FASNshRNA-Luc cells. B,
quantitative analysis of metastasis (estimated by total luciferase counts per animal) in
athymic nude mice injected i.v. with HT29-NTC-Luc or HT29-FASNshRNA-Luc cells. C,
representative images of histological analysis of lung micrometastasis in mice injected i.v.
with HT29-NTC-Luc or HT29-FASNshRNA-Luc cells. D, in vivo total-body
bioluminescence images of athymic nude mice in dorsal and ventral positions (IVIS@
Imaging System) injected i.v. with KM20-NTC-Luc/GFP or KM20-FASNshRNA-Luc/GFP
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cells. E, quantitative analysis of metastasis (estimated by total luciferase counts per animal)
in athymic nude mice injected i.v. with KM20-NTC-Luc/GFP or KM20-FASNshRNA-Luc/
GFP cells. F, representative images of histological analysis (H&E staining) of lung
micrometastasis in athymic nude mice injected i.v. with KM20-NTC-Luc/GFP or KM20-
FASNshRNA-Luc/GFP cells.
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